Investigational · Not FDA-approved

The GLP-1/GIP peptide built for more than weight loss.

Brenipatide (LY-3537031) is an investigational dual GLP-1/GIP peptide from Eli Lilly, designed for a long half-life. Its lead Phase 3 trials target alcohol use disorder and depression, not obesity. It is not FDA-approved and not available to buy, compound, or prescribe today.

brenipatide injection telehealth
Illustrative image. Brenipatide is investigational and not available by prescription or telehealth.
Phase 3
Current clinical stage (AUD, MDD)
~9–12 days
Reported half-life (Phase 1)
2029+
Earliest plausible FDA decision (our estimate, not Lilly guidance)
FDA status: investigational, in clinical trials

Brenipatide is not FDA-approved for any use. Eli Lilly is studying it in clinical trials — most prominently Phase 3 programs in alcohol use disorder and major depressive disorder. It isn't sold through pharmacies, compounders, or peptide suppliers.

This summary is based on public company disclosures, the ClinicalTrials.gov registry, and published research — it isn't an official FDA determination, and no efficacy results have been published yet.

As of October 24, 2026, we found no public report of an FDA expedited-program designation (such as Breakthrough or Fast Track) or of a meeting outcome for brenipatide. Sponsors don't always disclose such interactions, so that is not proof none has occurred.

The only legitimate way to receive brenipatide is by enrolling in one of Lilly's clinical trials. Material sold online "for research use only" isn't manufactured or quality-controlled for human use, and buying it carries real safety and legal risk.
What it is

A next-generation incretin peptide.

Brenipatide is an investigational medicine from Eli Lilly, developed under the code name LY-3537031. It's a dual agonist of the GLP-1 and GIP receptors — the same two targets as tirzepatide — but designed for a long half-life so it can be dosed less often. It's still in clinical trials and has not been approved by the FDA.

This page explains what brenipatide is, what it's being studied for, how it's thought to work, and exactly where it stands with regulators. It's written to help people understand the drug — not to sell it, and not as medical advice.

  • — Brenipatide activates two incretin receptors at once — GLP-1R and GIPR. It comes out of the same Eli Lilly peptide research program that produced tirzepatide (already approved) and retatrutide (a triple agonist still in development). 8
  • — What sets it apart is duration. A modified backbone — reportedly swapping in an unusual amino acid and adding a fatty-acid anchor — makes the molecule resist breakdown in the body. In Lilly's Phase 1 study, the reported half-life was about 9–12 days, which supported weekly maintenance dosing; earlier descriptions had called it once-monthly. 2
  • — Unlike most drugs in its class, brenipatide wasn't primarily built for weight loss. Lilly has pointed to its potential in neuroscience conditions, and its most advanced trials are in alcohol use disorder and depression — unusual lead indications for a GLP-1/GIP molecule.
Spec sheet
Developer
Eli Lilly
Type
Dual GLP-1R / GIPR agonist, synthetic peptide
Code name
LY-3537031
CAS number
2408921-49-1
Reported half-life
~9–12 days (Phase 1)
Uses under study

What it's being studied for.

The list below is what brenipatide is being studied for in clinical trials — not uses the FDA has approved. No efficacy results have been published yet, so this describes the research program, not a proven effect.

Alcohol use disorder 1
the most advanced program — two Phase 3 trials, both recruiting.
Depression and other psychiatric conditions
two Phase 3 trials in major depressive disorder are recruiting, and Phase 2 trials are studying bipolar disorder and schizophrenia.
Substance use beyond alcohol
Phase 2 trials are studying opioid use disorder and relapse prevention in people who have quit smoking — all pointing toward reward and craving pathways in the brain.
Digestive and respiratory conditions
Phase 2 trials are studying irritable bowel syndrome (both IBS-D and IBS-C), asthma, and COPD.
Weight and metabolism
as a GLP-1/GIP agonist, it's expected to affect appetite and body weight — likely a secondary effect, not its lead purpose.

None of these uses is FDA-approved. Conditions like alcohol use disorder, depression, and IBS need care from a licensed professional — not a self-directed peptide.

Mechanism

How it's thought to work.

Mechanism

By activating both the GLP-1 and GIP receptors, brenipatide is expected to work the way tirzepatide does: helping the body release insulin only when blood sugar is high, easing digestion, and reducing appetite. Hitting both receptors together is thought to produce a bigger effect than either one alone. 8

Its neuroscience trials rest on a different piece of the same biology: GLP-1 signaling in the brain appears to quiet reward and craving circuits, the proposed link to reduced drinking and other cravings. This is a working theory under investigation — not a result Lilly has published for brenipatide specifically.

Administration in trials

In its trials, brenipatide is injected under the skin. The dosing schedule in the Phase 3 trials is set by Lilly's protocols and isn't stated in the registry; in Phase 1, a half-life of about 9–12 days supported weekly maintenance dosing.

It isn't FDA-approved, so there's no dosing guidance to give here. It's only available inside Lilly's clinical trials, where dose and schedule are set by the trial protocol, not by the person taking it.

What the trials measure
Drinking outcomes: in the alcohol program, the main measure is a reduction in heavy-drinking days. 1
Metabolic markers: as an incretin drug, body weight, blood glucose, and HbA1c are standard readouts of its metabolic activity.
Safety and tolerability: researchers track side effects throughout — especially the gastrointestinal effects common to this drug class.
Lilly presented Phase 1 safety data in September 2026 (212 participants across a range of body weights).2 No deaths or serious adverse events were reported. Gastrointestinal events — the class's typical effects, such as nausea, vomiting and diarrhea — occurred in 25% of both brenipatide and placebo participants. Dysesthesia (abnormal skin sensations) was reported in 15.2% of brenipatide participants and none on placebo, and four people stopped treatment because of adverse events.3 These are early, preliminary figures from a conference presentation, not a peer-reviewed publication, and safety in the people the Phase 3 trials are studying hasn't been published. This is not a statement that brenipatide is safe.
Trial tracker

Where brenipatide stands.

Topline data from the lead Phase 3 trials is expected in early 2028.7 A filing and FDA decision would follow, so we estimate 2029 at the earliest, assuming the trials succeed. Lilly has not announced a filing timeline.

Preclinical
LY-3537031
Phase 1
Multiple studies; data shown Sept 2026
Phase 2
Several programs recruiting
Phase 3
AUD, MDD · recruiting
FDA decision
Not before ~2029 (our estimate)
Registered Phase 2 and Phase 3 trials
NCT07219966 Phase 3 Moderate-to-severe alcohol use disorder Recruiting NCT07219953 Phase 3 Alcohol use disorder Recruiting NCT07412756 Phase 3 Major depressive disorder Recruiting NCT07775300 Phase 3 Major depressive disorder, relapse prevention Recruiting NCT07286175 Phase 2 Bipolar disorder Recruiting NCT07410507 Phase 2 Schizophrenia Recruiting NCT07420283 Phase 2 Opioid use disorder Recruiting NCT07223840 Phase 2 Relapse prevention after quitting smoking Recruiting NCT07545759 Phase 2 Irritable bowel syndrome with diarrhea (IBS-D) Recruiting NCT07545772 Phase 2 Irritable bowel syndrome with constipation (IBS-C) Recruiting NCT07219173 Phase 2 Uncontrolled moderate-to-severe asthma Recruiting NCT07759245 Phase 2 Moderate-to-severe COPD Recruiting

Status as listed on ClinicalTrials.gov on October 24, 2026; all trials are sponsored by Eli Lilly. Phase 1 studies are not shown.

Compounding & legality

Could brenipatide ever be compounded?

"Compounded" drugs aren't approved by the FDA — a pharmacy or outsourcing facility prepares them instead of the manufacturer, under one of two legal pathways.

503A — pharmacy compounding
State-licensed pharmacies or physicians prepare a drug for one named patient, on a prescription. Only allowed to copy an approved drug while it's on FDA's shortage list, or to use a substance on the 503A bulk-drug list.
503B — outsourcing facilities
FDA-registered facilities manufacture in larger batches, without a patient-specific prescription, under cGMP rules — but only using substances on the 503B bulks list.
Why it can't be compounded right now

Both pathways require either an FDA-approved reference drug to copy, or a spot on FDA's 503A/503B bulk-substance lists. Brenipatide has neither: it isn't FDA-approved, and we found no listing for it on either bulks list — it's still Eli Lilly's investigational, patent-protected molecule. FDA's advisory committee meeting on peptides in July 2026 did not include brenipatide. Today, there is no legal pathway to a compounded brenipatide.

The tirzepatide precedent

After tirzepatide (Lilly's Mounjaro/Zepbound) was approved, a supply shortage — added to FDA's shortage list in December 2022 — opened the door for 503A pharmacies to legally compound copies, and a wave of 503B facilities and telehealth clinics followed.5

That window closed once supply caught up: FDA declared the tirzepatide shortage resolved in October 2024 and ended 503B enforcement discretion for it in March 2025.4 On April 30, 2026, FDA proposed excluding tirzepatide, semaglutide and liraglutide from the 503B bulks list; comments closed June 29, 2026, and we found no final action as of October 24, 2026.6

What would have to change
01FDA approval — brenipatide would need to clear Phase 3 and be approved for at least one indication. Phase 3 data is expected in early 2028, so the earliest realistic timing is 2029.
02A supply gap or bulks-list nomination — only a declared shortage or a successful 503A/503B bulk-substance nomination would make compounding legal, and current FDA policy is moving to close that door for this drug class, not open it.
03Lilly's posture — Lilly has actively contested compounding of its other GLP-1 medicines; nothing suggests it would treat brenipatide differently once approved.

Anything sold online today as "brenipatide" for research or personal use is unauthorized, unregulated, and not verified to be the same molecule studied in Lilly's trials.

In the press

Press & industry coverage.

Psychiatric Times · News Early Brenipatide Data Shows Substance Use Treatment Potential Covers Lilly's Phase 1 presentation: weekly subcutaneous dosing, a half-life of 9–12 days, and tolerability. GEN · News Lilly's GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders Details the Phase 1 safety figures and the Phase 2 and Phase 3 programs. BioSpace · News Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder Reports that Phase 3 topline data is expected in early 2028 and that no efficacy results have been shown.
FAQ

Frequently asked questions.

Brenipatide (development code LY-3537031) is an investigational synthetic peptide from Eli Lilly. It's a dual agonist of the GLP-1 and GIP receptors — the same targets as tirzepatide — designed for a long half-life and given by subcutaneous injection.
No. Brenipatide is investigational and not approved by the FDA for any use. It is being studied in clinical trials, and no efficacy data has been published.
Its most advanced programs are Phase 3 trials in alcohol use disorder (two trials) and major depressive disorder (two trials). Phase 2 trials are studying bipolar disorder, schizophrenia, opioid use disorder, relapse prevention after quitting smoking, irritable bowel syndrome (IBS-D and IBS-C), asthma, and COPD.
Both activate the same GLP-1 and GIP receptors. Brenipatide's backbone is modified for resistance to breakdown, giving it a longer half-life, and it's being developed with a lead focus on neuroscience indications rather than obesity or diabetes.
Earlier descriptions called brenipatide once-monthly. Lilly's September 2026 Phase 1 data instead reported a half-life of about 9–12 days, which supported weekly maintenance dosing. The dosing schedule in the Phase 3 trials is set by Lilly's protocols and isn't stated in the trial registry.
Only through enrollment in one of Eli Lilly's clinical trials. It is not sold through pharmacies, compounders, or peptide suppliers; material sold online "for research use only" is not for human use.
Not under current law. Compounding requires either an FDA-approved reference drug or a spot on FDA's bulk-substance lists — brenipatide has neither. FDA's advisory committee meeting on peptides in July 2026 did not include brenipatide. That could only change after FDA approval, and even then would depend on a supply shortage or bulks-list nomination, which current FDA policy is moving away from for this drug class.
Only early data exists. Lilly's Phase 1 study (212 people) reported no deaths or serious adverse events, similar rates of gastrointestinal events on brenipatide and placebo (25% in both), and dysesthesia in 15.2% of brenipatide participants versus none on placebo. These are preliminary figures from a conference presentation, and safety in the Phase 3 populations hasn't been published. Consult a licensed healthcare professional before making any health decision.
It means the drug is still being tested in clinical trials and has not been reviewed or approved by the FDA for safety and effectiveness. Investigational drugs can fail at any stage and are not available outside of trials.
There's no confirmed date, and Lilly hasn't announced a filing timeline. Topline data from the lead Phase 3 trials is expected in early 2028, so the earliest realistic FDA decision is likely 2029 or later — and only if the trials succeed.
None has been publicly reported as of October 24, 2026 — we found no announced Breakthrough or Fast Track designation or meeting outcome. Sponsors don't always disclose their FDA interactions, so that is not proof that none has occurred.

Sources

1.
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder. — ClinicalTrials.gov, Phase 3, NCT07219966; status as of October 24, 2026. clinicaltrials.gov — NCT07219966
2.
Early Brenipatide Data Shows Substance Use Treatment Potential. — Psychiatric Times, September 18, 2026. psychiatrictimes.com — brenipatide Phase 1 data
3.
Lilly's GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders. — GEN, September 2026. genengnews.com — brenipatide Phase 1 safety data
4.
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. — U.S. Food and Drug Administration. fda.gov — GLP-1 compounder policy
5.
FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs. — Orrick, legal analysis, May 2026. orrick.com — GLP-1 compounding analysis
6.
FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. — U.S. Food and Drug Administration, April 30, 2026. fda.gov — 503B bulks list proposal
7.
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder. — BioSpace, September 22, 2026. biospace.com — Phase 3 timing
8.
Brenipatide — Eli Lilly and Company (drug development record). — AdisInsight, Springer. adisinsight.springer.com — brenipatide